摘要
目的观察黄芪、莪术配伍对人卵巢癌HO-8910原位癌抑瘤效果。方法选取已建立荧光蛋白转染的HO-8910卵巢癌原位癌动物模型(7组),分为模型组,阳性对照组(顺铂),黄芪组,莪术组,黄芪、莪术配伍(按照2∶1)高、中、低剂量组。用免疫组织化学法及Real time-PCR检测移植瘤组织中FGF-2、BCL-2蛋白及基因的表达。结果阳性对照组,黄芪组,莪术组,黄芪、莪术低剂量组,黄芪、莪术高剂量组肿瘤平均肿瘤重量较对照组皆明显减少,且有统计学差异(P<0.05),而黄芪、莪术高剂量组与阳性对照组比较,统计学分析有显著性差异(P<0.05);各给药组肿瘤组织中的FGF-2、BCL-2 mRNA表达明显低于阴性对照组,且有统计学差异(P<0.05);各给药组肿瘤组织中FGF-2蛋白表达明显低于阴性对照组(P<0.05);而各给药组肿瘤组织中BCL-2蛋白表达与阴性对照组相比较无统计学差异(P>0.05)。结论黄芪、莪术配伍使用在实验周期内对人卵巢癌HO-8910抑瘤效果明显(P<0.05),其作用机制可能与下调FGF-2、BCL-2的表达有关。
Objective To observe the effect of Radix Astragali,Rhizoma Zedoariae compatibility on human ovarian cancer HO-8910 cancer in situ tumor inhibitory effect.Methods Select the HO- 8910 ovarian carcinoma in situ animal models have been established fluorescent protein transfection（ 7 group）,including model group,positive control group（ Shun Bo）,Astragalus group,Astragalus root,Zedoary group,combination group（ on the basis of 2： 1） of low,middle and high dose.Dynamic measurement of each tumor volume,tumor metastasis,tumor inhibitory effect.The RNA and protein expression of FGF- 2 and BCL- 2 were detected by Real time- PCR and immunohistochemical method.Results The positive group,Astragalus group,Zedoary group,Astragalus,zedoary turmeric compatibility group of low dosage,Astragalus and Zedoary turmeric compatibility group of high dosage,tumor weight were lower than model group（ P〈0.05）,Astragalus and Zedoary turmeric compatibility group of high dosage tumor weights less than model group（ P〈0.05）; Compared with the model group the level of FGF- 2 and BCL- 2 mRNA and FGF-2 protein expression of average weakened Astragalus and Zedoary turmeric compatibility group and cisplatin group in transplanted tumor tissue（ P〈0.05）; but BCL- 2 protein expression of average weakened Astragalus and Zedoary turmeric compatibility group and cisplatin group in transplanted tumor tissue show no significant difference compared with the model control group（ P〈0.05）.Conclusion Astragalus root,Zedoary compatible inhibitory effect on human ovarian cancer HO- 8910 in experimental period was obvious（ P〈0.05）,the action mechanism of the expression may be associated with the downregulation of FGF- 2 and BCL- 2.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2015年第7期1537-1540,共4页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(No.81073072
No.81373990)
江苏省高校自然科学基金项目(No.14KJB360004)
南京中医药大学青年自然科学基金项目(13XZR07)
